Dabigatran-associated subdural hemorrhage: Using thromboelastography (TEG®) to guide decision-making

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 2, 2014, Pages 80-83

  Neyens, Ron ^a   Bohm, Nicole ^b   Cearley, Madelyne ^a   Andrews, Charles ^c   Chalela, Julio ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dabigatran; FEIBA; Intracranial hemorrhage; Prothrombin complex concentrates; Thromboelastography

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; CREATININE; DABIGATRAN;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CREATININE BLOOD LEVEL; HEADACHE; HEMOSTASIS; HOSPITAL ADMISSION; HUMAN; LETHARGY; LIMB WEAKNESS; MALE; MEDICAL DECISION MAKING; NEUROLOGICAL EQUIPMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REPEAT PROCEDURE; SUBDURAL EVACUATING PORT SYSTEM; SUBDURAL HEMATOMA; THROMBIN TIME; THROMBOELASTOGRAPHY; VERY ELDERLY;

AGED, 80 AND OVER; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; DECISION MAKING; HEMATOMA, SUBDURAL; HUMANS; THROMBELASTOGRAPHY;

EID: 84894669560     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0933-9     Document Type: Article

References (12)

1. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M et al (2010) Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116-1127
2. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM (2012) Impact of dabigatran on a large panel of routine or specific coagulation assays. laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107:985-997
3. MacDonald SG, Luddington RJ (2010) Critical factors contributing to the thromboelastography trace. Semin Thromb Hemost 36:712-722
4. Taketomi T, Szlam F, Vinten-Johansen J, Levy JH, Tanaka KA (2007) Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors. Blood Coagul Fibrinolysis 18:761-767
5. Xu Y, Wu W, Wang L, Chintala M, Plump AS, Ogletree ML et al (2013) Differential profiles of thrombin inhibitors in the thrombin generation assay and thromboelastrography in vitro. Blood Coagul Fibrinolysis 24(3):332-338
6. Engstrom M, Rundgren M, Schott U (2010) An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin time. Acta Anaesthesiol Scand 54:86-91
7. Schmitz ML, St Amour ED, Harness HL, McKamie WA, Johnson CE (2009) RapidTEG observation suggests activation of factor VII may overcome argatroban-induced coagulopathy. J Cardiothorac Vasc Anesth 23:752-753
8. Cotton BA, McCarthy JJ, Holcomb JB (2011) Acutely injured patients on dabigatran. N Engl J Med 365:2039-2040
9. Kopitnik TA, de Andrade R, Gold MA, Nugent GR (1989) Pressure changes within a chronic subdural hematoma during hemodialysis. Surg Neurol 32:289-293
10. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Perond G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemos 108:217-224
11. Dager W, Roberts W (2011) Reversing dabigatran with FEIBA in a patient with a transseptal perforation during cardiac ablation, Abstract. Crit Care Med 39:273
12. Tanaka KA, Szlam F, Koyama K, Levy JH (2010) Argatroban "reversal" is caused by nonphysiologic stimulation of coagulation, not activated factor VII. J Cardiothorac Vasc Anesth 24:1026-1027